Vitrolife´s CEO sells a portion of his shareholding

Vitrolife's CEO Thomas Axelsson has today sold 50,000 shares worth SEK 9.45 million. The remaining number of shares amounts to 50,500 shares.

"The Vitrolife share has developed very positively since I acquired the shares in 2012 and I therefore choose to realize part of the profit for private financial reasons," says Thomas Axelsson, CEO of Vitrolife AB. The transaction will be reported to The Swedish Financial Supervisory Authority (Finansinspektionen) according to current regulations.

Gothenburg, February 11, 2020
VITROLIFE AB (publ)
Thomas Axelsson, CEO

Queries should be addressed to:
Thomas Axelsson, CEO, tel 46 31 721 80 01
Mikael Engblom, CFO, tel 46 31 721 80 14

This information is information that Vitrolife AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 12:00 CET on February 11, 2020..

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.

_________________________________________________________________________________________________________________

Vitrolife is an international medical device Group. Vitrolife develops, produces and markets medical devices for assisted reproduction.

Vitrolife has approximately 400 employees and the company's products are sold in about 110 markets. The company is headquartered in Gothenburg, Sweden, and there are also offices in Australia, Belgium, China, Denmark, France, Germany, Italy, Japan, United Kingdom and USA. The Vitrolife share is listed on NASDAQ Stockholm.

Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity number 556354-3452. Tel: 46 31 721 80 00. Fax: 46 31 721 80 99. E-mail: info@vitrolife.com. Website: www.vitrolife.com/